SCMP: AstraZeneca’s first vaccine-manufacturing facility in China will be located in Beijing BioPark and offer the opportunity for joint ventures with local tech and medical start-ups. Beijing also vowed to make it easier for foreign manufacturers to launch innovative drugs and participate in public procurement, in a 20-point action plan designed to retain and further entice foreign investment. 《南華早報》：阿斯特捷利康在中國的首個疫苗生產基地將設在北京生物園區，並為與當地科技和醫療新創公司建立合資企業提供機會。北京還承諾為外國製造商推出創新藥物和參與政府採購提供便利，並製定了一項20點行動計劃，旨在保留和進一步吸引外國投資.